Pilot study of the effect of romiplostim on child health-related quality of life (HRQoL) and parental burden in immune thrombocytopenia (ITP)

Robert J. Klaassen, Susan D. Mathias, George Buchanan, James Bussel, Robert Deuson, Nancy L. Young, Anderson Collier, Lisa Bomgaars, Victor Blanchette

Research output: Contribution to journalArticle

32 Citations (Scopus)

Abstract

Background: Childhood ITP can have a negative impact on the child and his/her family even though it is typically a benign disorder with low risk of serious bleeding. In adults and now children, romiplostim increases the platelet count without significant adverse effects. In this study, the impact of romiplostim treatment on the HRQoL of children with chronic ITP was assessed using the Kid's ITP Tools (KIT). Procedure: Subjects 1-18 years old, with chronic ITP (>6 months), were enrolled in a multi-center, randomized, double-blind, placebo-controlled phase 1/2 treatment study with romiplostim (reported elsewhere). Subjects and/or proxies completed the KIT at baseline, week 5, and week 13. Scores were computed for child self-report (children >7 years), proxy-report, and parent impact. Changes in mean scores from baseline to week 13 were computed. Results: Twenty-two children (17 receiving romiplostim, 5 placebo) and/or their parents provided data. Change in mean scores demonstrated significant improvement in HRQoL for romiplostim versus placebo for parent impact (24±17 vs. -6±8; P=0.008). Change scores for child self-report trended toward improvement with romiplostim and decreased with placebo (5±10 vs. -7±17; P=0.29). Romiplostim proxy-report mean change scores were 6 points higher than placebo (8±16 vs. 2±12; P=0.50). Conclusions: Romiplostim significantly reduced parental burden in this study. Whether the same and/or additional improvements in HRQoL would be demonstrated by a larger, longer study of romiplostim-treated children with ITP remains to be determined.

Original languageEnglish (US)
Pages (from-to)395-398
Number of pages4
JournalPediatric Blood and Cancer
Volume58
Issue number3
DOIs
StatePublished - Mar 2012

Fingerprint

Idiopathic Thrombocytopenic Purpura
Quality of Life
Placebos
Proxy
Self Report
Inosine Triphosphate
Child Health
romiplostim
Platelet Count
Parents
Hemorrhage

Keywords

  • Idiopathic
  • Parents
  • Purpura
  • Quality of life
  • Questionnaires
  • Thrombocytopenic

ASJC Scopus subject areas

  • Oncology
  • Pediatrics, Perinatology, and Child Health
  • Hematology

Cite this

Pilot study of the effect of romiplostim on child health-related quality of life (HRQoL) and parental burden in immune thrombocytopenia (ITP). / Klaassen, Robert J.; Mathias, Susan D.; Buchanan, George; Bussel, James; Deuson, Robert; Young, Nancy L.; Collier, Anderson; Bomgaars, Lisa; Blanchette, Victor.

In: Pediatric Blood and Cancer, Vol. 58, No. 3, 03.2012, p. 395-398.

Research output: Contribution to journalArticle

Klaassen, Robert J. ; Mathias, Susan D. ; Buchanan, George ; Bussel, James ; Deuson, Robert ; Young, Nancy L. ; Collier, Anderson ; Bomgaars, Lisa ; Blanchette, Victor. / Pilot study of the effect of romiplostim on child health-related quality of life (HRQoL) and parental burden in immune thrombocytopenia (ITP). In: Pediatric Blood and Cancer. 2012 ; Vol. 58, No. 3. pp. 395-398.
@article{83013828683e4b2586f020214f3ee8e7,
title = "Pilot study of the effect of romiplostim on child health-related quality of life (HRQoL) and parental burden in immune thrombocytopenia (ITP)",
abstract = "Background: Childhood ITP can have a negative impact on the child and his/her family even though it is typically a benign disorder with low risk of serious bleeding. In adults and now children, romiplostim increases the platelet count without significant adverse effects. In this study, the impact of romiplostim treatment on the HRQoL of children with chronic ITP was assessed using the Kid's ITP Tools (KIT). Procedure: Subjects 1-18 years old, with chronic ITP (>6 months), were enrolled in a multi-center, randomized, double-blind, placebo-controlled phase 1/2 treatment study with romiplostim (reported elsewhere). Subjects and/or proxies completed the KIT at baseline, week 5, and week 13. Scores were computed for child self-report (children >7 years), proxy-report, and parent impact. Changes in mean scores from baseline to week 13 were computed. Results: Twenty-two children (17 receiving romiplostim, 5 placebo) and/or their parents provided data. Change in mean scores demonstrated significant improvement in HRQoL for romiplostim versus placebo for parent impact (24±17 vs. -6±8; P=0.008). Change scores for child self-report trended toward improvement with romiplostim and decreased with placebo (5±10 vs. -7±17; P=0.29). Romiplostim proxy-report mean change scores were 6 points higher than placebo (8±16 vs. 2±12; P=0.50). Conclusions: Romiplostim significantly reduced parental burden in this study. Whether the same and/or additional improvements in HRQoL would be demonstrated by a larger, longer study of romiplostim-treated children with ITP remains to be determined.",
keywords = "Idiopathic, Parents, Purpura, Quality of life, Questionnaires, Thrombocytopenic",
author = "Klaassen, {Robert J.} and Mathias, {Susan D.} and George Buchanan and James Bussel and Robert Deuson and Young, {Nancy L.} and Anderson Collier and Lisa Bomgaars and Victor Blanchette",
year = "2012",
month = "3",
doi = "10.1002/pbc.23312",
language = "English (US)",
volume = "58",
pages = "395--398",
journal = "Pediatric Blood and Cancer",
issn = "1545-5009",
publisher = "Wiley-Liss Inc.",
number = "3",

}

TY - JOUR

T1 - Pilot study of the effect of romiplostim on child health-related quality of life (HRQoL) and parental burden in immune thrombocytopenia (ITP)

AU - Klaassen, Robert J.

AU - Mathias, Susan D.

AU - Buchanan, George

AU - Bussel, James

AU - Deuson, Robert

AU - Young, Nancy L.

AU - Collier, Anderson

AU - Bomgaars, Lisa

AU - Blanchette, Victor

PY - 2012/3

Y1 - 2012/3

N2 - Background: Childhood ITP can have a negative impact on the child and his/her family even though it is typically a benign disorder with low risk of serious bleeding. In adults and now children, romiplostim increases the platelet count without significant adverse effects. In this study, the impact of romiplostim treatment on the HRQoL of children with chronic ITP was assessed using the Kid's ITP Tools (KIT). Procedure: Subjects 1-18 years old, with chronic ITP (>6 months), were enrolled in a multi-center, randomized, double-blind, placebo-controlled phase 1/2 treatment study with romiplostim (reported elsewhere). Subjects and/or proxies completed the KIT at baseline, week 5, and week 13. Scores were computed for child self-report (children >7 years), proxy-report, and parent impact. Changes in mean scores from baseline to week 13 were computed. Results: Twenty-two children (17 receiving romiplostim, 5 placebo) and/or their parents provided data. Change in mean scores demonstrated significant improvement in HRQoL for romiplostim versus placebo for parent impact (24±17 vs. -6±8; P=0.008). Change scores for child self-report trended toward improvement with romiplostim and decreased with placebo (5±10 vs. -7±17; P=0.29). Romiplostim proxy-report mean change scores were 6 points higher than placebo (8±16 vs. 2±12; P=0.50). Conclusions: Romiplostim significantly reduced parental burden in this study. Whether the same and/or additional improvements in HRQoL would be demonstrated by a larger, longer study of romiplostim-treated children with ITP remains to be determined.

AB - Background: Childhood ITP can have a negative impact on the child and his/her family even though it is typically a benign disorder with low risk of serious bleeding. In adults and now children, romiplostim increases the platelet count without significant adverse effects. In this study, the impact of romiplostim treatment on the HRQoL of children with chronic ITP was assessed using the Kid's ITP Tools (KIT). Procedure: Subjects 1-18 years old, with chronic ITP (>6 months), were enrolled in a multi-center, randomized, double-blind, placebo-controlled phase 1/2 treatment study with romiplostim (reported elsewhere). Subjects and/or proxies completed the KIT at baseline, week 5, and week 13. Scores were computed for child self-report (children >7 years), proxy-report, and parent impact. Changes in mean scores from baseline to week 13 were computed. Results: Twenty-two children (17 receiving romiplostim, 5 placebo) and/or their parents provided data. Change in mean scores demonstrated significant improvement in HRQoL for romiplostim versus placebo for parent impact (24±17 vs. -6±8; P=0.008). Change scores for child self-report trended toward improvement with romiplostim and decreased with placebo (5±10 vs. -7±17; P=0.29). Romiplostim proxy-report mean change scores were 6 points higher than placebo (8±16 vs. 2±12; P=0.50). Conclusions: Romiplostim significantly reduced parental burden in this study. Whether the same and/or additional improvements in HRQoL would be demonstrated by a larger, longer study of romiplostim-treated children with ITP remains to be determined.

KW - Idiopathic

KW - Parents

KW - Purpura

KW - Quality of life

KW - Questionnaires

KW - Thrombocytopenic

UR - http://www.scopus.com/inward/record.url?scp=84855770524&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84855770524&partnerID=8YFLogxK

U2 - 10.1002/pbc.23312

DO - 10.1002/pbc.23312

M3 - Article

C2 - 21910213

AN - SCOPUS:84855770524

VL - 58

SP - 395

EP - 398

JO - Pediatric Blood and Cancer

JF - Pediatric Blood and Cancer

SN - 1545-5009

IS - 3

ER -